Mount Sinai Study Reveals Current Cardiac Risk Screening Tools Fail to Identify Nearly Half of Heart Attack Patients

A groundbreaking study led by researchers at the Icahn School of Medicine at Mount Sinai has uncovered a critical vulnerability in modern preventative cardiology, revealing that the most widely utilized cardiac screening methods fail to identify nearly 50 percent of individuals who eventually suffer a heart attack. The findings, published on November 21 in the Journal of the American College of Cardiology: Advances, suggest that the current medical reliance on statistical risk calculators and patient-reported symptoms may be fundamentally inadequate for preventing primary cardiac events in seemingly healthy adults. According to the research team, these results highlight a significant disconnect between population-based risk assessments and the biological reality of individual arterial health, potentially leaving millions of patients without the protective treatments they require.

The Evolution and Limitations of Cardiovascular Risk Assessment

For decades, the cornerstone of preventative cardiology has been the use of risk scores to determine which patients should receive aggressive interventions, such as statin therapy or intensive blood pressure management. The most prominent of these tools is the Atherosclerotic Cardiovascular Disease (ASCVD) risk score, which was developed to estimate a patient’s 10-year risk of experiencing a major cardiac event. By factoring in variables such as age, sex, race, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, diabetes status, and smoking history, the ASCVD score provides a percentage that guides clinical decision-making.

In recent years, the medical community has introduced more sophisticated tools, such as the PREVENT (Predicting Risk of cardiovascular Disease events) equations. Developed by the American Heart Association, PREVENT was designed to offer a more nuanced perspective by incorporating additional variables, including kidney function and social determinants of health, while removing race as a biological variable. Despite these advancements, the Mount Sinai study indicates that even these modernized tools remain "gatekeepers" that frequently fail to detect the "silent" progression of heart disease.

The core of the issue lies in the fact that these scores are derived from large-scale population data. While they are effective at predicting how many people in a group of 10,000 might have a heart attack, they struggle to pinpoint exactly which individual within that group is at immediate risk. This statistical "blind spot" means that many patients who are biologically predisposed to a heart attack—due to the presence of arterial plaque—are classified as "low risk" simply because they do not yet fit the clinical profile of a high-risk patient.

Methodology: A Retrospective Analysis of First-Time Heart Attacks

To investigate the efficacy of these screening tools, the Mount Sinai research team conducted a detailed retrospective review of 474 patients. The study focused on a specific and highly relevant demographic: individuals younger than 66 years of age who had no known history of coronary artery disease prior to their first heart attack. These patients were treated at either Mount Sinai Morningside or The Mount Sinai Hospital between January 2020 and July 2025.

The researchers meticulously reconstructed the clinical profiles of these patients as they would have appeared just 48 hours before their cardiac event. By collecting demographic data, medical histories, cholesterol levels, and blood pressure readings, the team was able to calculate what each patient’s ASCVD and PREVENT scores would have been during a routine check-up immediately preceding their heart attack.

The patients were categorized into four risk tiers based on their calculated 10-year risk:

• Low Risk: Less than 5 percent
• Borderline Risk: 5 to 7.5 percent
• Intermediate Risk: 7.5 to 20 percent
• High Risk: Greater than 20 percent

Under current clinical guidelines, patients in the "low" and "borderline" categories are rarely recommended for advanced diagnostic testing or aggressive preventative medication. They are typically reassured by their physicians that their cardiovascular health is stable.

The Data: A Stark Gap in Preventative Efficacy

The results of the simulation were alarming to the researchers and have profound implications for public health. The analysis revealed that if these 474 heart attack victims had been screened just two days before their emergency, nearly half (45 percent) would not have met the criteria for preventative therapy or further diagnostic investigation under the ASCVD guidelines.

The performance of the newer PREVENT tool was even more concerning in this specific cohort. When the researchers applied the PREVENT equations, the proportion of "missed" patients rose to 61 percent. This suggests that while PREVENT may be useful for broader health assessments, it may actually be less sensitive than the older ASCVD score in identifying individuals on the verge of a first-time heart attack.

Furthermore, the study addressed the role of symptoms in early detection. A common medical assumption is that patients will experience "warning signs"—such as chest pain (angina) or shortness of breath—as their heart disease progresses. However, the Mount Sinai data told a different story. Sixty percent of the study participants reported that their symptoms began fewer than two days before their heart attack. For many, the heart attack itself was the very first sign that anything was wrong. This confirms that atherosclerosis—the buildup of plaque in the arteries—is often a "silent killer" that does not manifest symptoms until the plaque ruptures and causes a total blockage.

Expert Reactions: The Call for a Paradigm Shift

The study’s lead authors argue that these findings necessitate a fundamental reconsideration of how heart disease is screened in the United States and beyond. Dr. Amir Ahmadi, MD, Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai and the study’s corresponding author, emphasized that the current model is reactive rather than truly preventative.

"Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients," Dr. Ahmadi stated. He noted that if these patients had walked into a clinic 48 hours before their life-threatening event, they would have been told they were fine. "It may be time to fundamentally reconsider this model and move toward atherosclerosis imaging to identify the silent plaque—early atherosclerosis—before it has a chance to rupture."

Dr. Anna Mueller, MD, an internal medicine resident at Mount Sinai and the study’s first author, echoed these sentiments, pointing out the inherent flaw in using large-scale statistics for individualized care. "This study highlights that a lower risk score, along with not having classic heart attack symptoms like chest pain or shortness of breath, is no guarantee of safety on an individual level," Mueller explained. She suggested that the medical community should shift its focus from identifying symptomatic heart disease to detecting the physical presence of plaque itself.

The Case for Advanced Imaging and Early Detection

The Mount Sinai study adds significant weight to the growing movement within cardiology advocating for the use of advanced imaging technologies as a primary screening tool. While blood tests and blood pressure readings provide indirect clues about heart health, imaging offers a direct look at the state of the coronary arteries.

Two primary technologies are often cited as potential successors or supplements to traditional risk scores:

1. Coronary Artery Calcium (CAC) Scoring: A non-invasive CT scan that measures the amount of calcified plaque in the heart’s arteries. A score of zero indicates a very low risk of a heart attack, while higher scores can trigger immediate preventative action, even in patients who appear healthy by traditional metrics.
2. Coronary Computed Tomography Angiography (CCTA): A more detailed imaging test that can identify "soft" or non-calcified plaque, which is often more prone to rupturing and causing sudden heart attacks.

Historically, these tests have not been used as universal screening tools due to concerns over cost and radiation exposure. However, proponents argue that the cost of a heart attack—both in terms of human life and healthcare expenditures—far outweighs the cost of a preventative scan.

Chronology of the Heart Disease Prevention Model

The reliance on risk scores is a relatively recent development in the history of medicine. The timeline of how we arrived at the current (and now questioned) model provides context for why this study is so disruptive:

• 1948: The Framingham Heart Study begins, establishing the link between high blood pressure, high cholesterol, and heart disease.
• 1960s-1990s: Various iterations of the Framingham Risk Score become the gold standard for predicting heart disease.
• 2013: The American College of Cardiology (ACC) and the American Heart Association (AHA) introduce the ASCVD Pooled Cohort Equations, moving toward a more comprehensive 10-year risk assessment.
• 2018: Guidelines are updated to allow for CAC scoring in "tie-breaker" scenarios where a patient’s risk is uncertain.
• 2023: The PREVENT equations are introduced to modernize risk assessment and include kidney health and social factors.
• 2024: The Mount Sinai study reveals that despite these refinements, up to 61% of first-time heart attack victims are still categorized as low risk just days before their event.

Implications for Public Health and Clinical Guidelines

The implications of this study are vast. If the medical community continues to rely on tools that miss 45 to 61 percent of at-risk individuals, the rate of "sudden" heart attacks in young and middle-aged adults is unlikely to decline significantly.

From a policy perspective, this research may influence future updates to the ACC/AHA clinical guidelines. There is a potential for a stronger recommendation for imaging in younger adults (aged 40–60) who currently fall into the "low risk" category but may be harboring significant silent plaque.

Furthermore, the study challenges the "reassurance culture" in primary care. Currently, a patient with a low ASCVD score who reports no symptoms is often dismissed with a clean bill of health. The Mount Sinai data suggests that this reassurance may be premature. Instead, physicians may need to engage in more nuanced discussions about the limitations of risk scores and the potential benefits of direct arterial visualization.

Conclusion: Moving Toward Individualized Prevention

The Mount Sinai study serves as a stark reminder that in the realm of cardiovascular health, "low risk" does not mean "no risk." The failure of traditional screening tools to capture nearly half of future heart attack victims indicates a need for a technological and philosophical shift in how we approach heart disease prevention.

As researchers continue to refine imaging techniques and explore the use of artificial intelligence to better predict plaque rupture, the goal remains clear: to move away from reactive medicine and toward a proactive model that identifies and treats the disease long before it reaches a crisis point. For the 474 patients in this study, the current system failed to provide a warning. The hope of the Mount Sinai team is that their findings will lead to a new standard of care where such warnings are caught in time to save lives.